117 related articles for article (PubMed ID: 24128789)
1. High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma.
Falkenius J; Lundeberg J; Johansson H; Tuominen R; Frostvik-Stolt M; Hansson J; Egyhazi Brage S
Melanoma Res; 2013 Dec; 23(6):452-60. PubMed ID: 24128789
[TBL] [Abstract][Full Text] [Related]
2. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
4. Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay.
Włodzimierz R; Rutkowski P; Nowecki ZI; Kulik J; Nasierowska-Guttmejer A; Siedlecki JA
Ann Surg Oncol; 2004 Nov; 11(11):988-97. PubMed ID: 15525828
[TBL] [Abstract][Full Text] [Related]
5. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
6. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma.
Rangel J; Torabian S; Shaikh L; Nosrati M; Baehner FL; Haqq C; Leong SP; Miller JR; Sagebiel RW; Kashani-Sabet M
J Clin Oncol; 2006 Oct; 24(28):4565-9. PubMed ID: 17008696
[TBL] [Abstract][Full Text] [Related]
8. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
[TBL] [Abstract][Full Text] [Related]
9. Predicting clinical outcome through molecular profiling in stage III melanoma.
John T; Black MA; Toro TT; Leader D; Gedye CA; Davis ID; Guilford PJ; Cebon JS
Clin Cancer Res; 2008 Aug; 14(16):5173-80. PubMed ID: 18698035
[TBL] [Abstract][Full Text] [Related]
10. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
[TBL] [Abstract][Full Text] [Related]
11. Sarcopenia as a prognostic factor among patients with stage III melanoma.
Sabel MS; Lee J; Cai S; Englesbe MJ; Holcombe S; Wang S
Ann Surg Oncol; 2011 Dec; 18(13):3579-85. PubMed ID: 21822551
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of galectin-3 in primary cutaneous melanoma.
Buljan M; Šitum M; Tomas D; Milošević M; Krušlin B
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1174-81. PubMed ID: 21175876
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers vs conventional histological analysis to detect lymph node micrometastases in bladder cancer: a real improvement?
Gazquez C; Ribal MJ; Marín-Aguilera M; Kayed H; Fernández PL; Mengual L; Alcaraz A
BJU Int; 2012 Nov; 110(9):1310-6. PubMed ID: 22416928
[TBL] [Abstract][Full Text] [Related]
15. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes.
Satzger I; Völker B; Meier A; Schenck F; Kapp A; Gutzmer R
Am J Surg Pathol; 2007 Aug; 31(8):1175-80. PubMed ID: 17667539
[TBL] [Abstract][Full Text] [Related]
17. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma.
Piras F; Murtas D; Minerba L; Ugalde J; Floris C; Maxia C; Colombari R; Perra MT; Sirigu P
Histopathology; 2007 Jun; 50(7):835-42. PubMed ID: 17543072
[TBL] [Abstract][Full Text] [Related]
18. Metallothionein-overexpression as a prognostic marker in melanoma.
Weinlich G
G Ital Dermatol Venereol; 2009 Feb; 144(1):27-38. PubMed ID: 19218909
[TBL] [Abstract][Full Text] [Related]
19. Diversity of stage III melanoma in the era of sentinel lymph node biopsy.
Egger ME; Callender GG; McMasters KM; Ross MI; Martin RC; Edwards MJ; Urist MM; Noyes RD; Sussman JJ; Reintgen DS; Stromberg AJ; Scoggins CR
Ann Surg Oncol; 2013 Mar; 20(3):956-63. PubMed ID: 23064795
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
